Relationship between overall survival and progression-free survival with 18 F-FDG PET/CT metabolic parameters in metastatic breast cancer patients treated with CDK 4/6 inhibitors

BÜLBÜL O., Aydin E., Nak D.

IRISH JOURNAL OF MEDICAL SCIENCE, 2026 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1007/s11845-026-04505-w
  • Dergi Adı: IRISH JOURNAL OF MEDICAL SCIENCE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest)
  • Erciyes Üniversitesi Adresli: Evet

Özet

Background Combining CDK 4/6 inhibitors with endocrine therapy (ET) extends progression-free survival (PFS) and overall survival (OS) in hormone receptor (HR) positive, human epidermal growth factor receptor-2 (HER2) negative metastatic breast cancer. We aimed to explore the relationship between metabolic tumor volume (MTV), total lesion glycolysis (TLG), and PFS/OS in these patients. Methods MTV and TLG were measured from baseline 18 F-fluorodeoxyglucose (18-FDG) positron emission tomography/computed tomography (PET/CT) of 87 HR-positive/HER2-negative metastatic breast cancer patients and their effects on survival were analyzed using Kaplan-Meier methods. Results The median OS was 42.0 months for patients with MTV < 121.7 cm & sup3; and 24.6 months with >= 121.7 cm(3) (p = 0.001). The median OS was 40.3 months for patients with TLG < 732.4 g and 24.6 months with >= 732.4 g (p = 0.006). The median OS for patients with an ECOG score of 0 was 53.6 months, while for those with an ECOG score of 1-2, it was 26.4 months (p = 0.005). Age >= 60 years (HR = 5.11, p = 0.002) and ECOG score > 0 (HR = 3.38, p = 0.011) are independent predictors of PFS. Conclusions Baseline 18 F-FDG PET/CT may provide prognostic insights in HR+/HER2- metastatic breast cancer. High MTV and TLG are associated with poorer OS in univariate analyses but not in multivariable analyses. ECOG score > 0 and age >= 60 years are independent predictors of PFS.